ABSTRACT -The antimetastatic effect of cepharanthin with or without 5-fluorouracil (5-FU) was examined in an experimental model of lung metastasis induced by Lewis lung carcinoma (3LL) in C57BL/6crSlc mice. Injection of cepharanthin i.p. after re moval of the implanted primary tumor inhibited the development of lung metastases. Combination therapy with cepharanthin plus 5-FU inhibited significantly the lung metastases. Lung metastases were inhibited by i.v. injection of peritoneal macro phages activated with cepharanthin. Cepharanthin depressed aniline hydroxylase and aminopyrine demethylase activities of the hepatic microsomal drug-metabolizing sys tem in tumor-bearing mice. Moreover, the concentration of 5-FU in the tissues (lung, liver, kidney, spleen and blood) was increased significantly by coadministration of cepharanthin. A possible mechanism of the inhibition of lung metastases by treatment with cepharanthin may be that this drug acts through macrophage activation and de pression of the hepatic microsomal drug-metabolizing system. These findings raise the possibility that combination therapy with cepharanthin plus 5-FU may have clini cal value in the prevention of cancer metastasis.
The pathogenesis of metastasis involves many complex biological processes, and its outcome depends on the interaction of tumor cells with their host and is influenced by var ious factors in the metastatic step (1, 2) . The role of host defense in the control of metasta sis is not well-understood. It might be possible to eradicate or prevent micrometastases by im munological modulation of the host defense mechanism. Indeed, biological response modi fiers such as polysaccharides extracted from plants (3, 4) , bacterial cellular components (5) , Corynebacterium parvum (6) , BCG (7) and water extract from herbal medicine (8) that activate the reticuloendothelial system of the host have been found to inhibit develop ment of metastases. A pyrimidine antitumor drug, 5-fluorouracil (5-FU) has been proven to be one of the most useful drugs available in clinical oncology. A biscoclaurine alkaloid, cepharanthin, has been shown to affect cell membranes (9) (10) (11) and alter the biomem brane movement of Ca++ (12) . Shiraishi et al. (13) described the effect of cepharanthin on a multidrug resistance KB human cancer cell line. Kato and Suzumura (14) have reported that cepharanthin enhanced the antitumor activity of vincristine. Ono et al. (15) demon strated that intratumoral administration of cepharanthin significantly inhibited the growth of Sarcoma-180 solid tumor in mice. Recently, Fujimura et al. (16) showed that cepharanthin overcomes doxorubicin resistance in doxo rubicin-resistant murine P388 leukemia cells in vitro and in vivo. Shimura (17) demonstrated that cepharanthin enhanced phagocytosis and ingestion of polystyrene latex beads into the peritoneal macrophages of mice after i.p. in jection. However, the mechanism of the ac tion of cepharanthin on tumors, is still un clear.
Therefore in the present study, we attempt ed to determine the antimetastatic effect of cepharanthin on Lewis lung carcinoma and the possible mechanisms of its action.
MATERIALS AND METHODS

Animals
Five-week-old females C57BL/6crSlc mice (SPF), weighing 19 to 22 g, were obtained from Shizuoka Laboratory Animal Center (Japan). They were maintained on an CE-2 pellet diet (Clea Japan, Inc., Japan) and water ad libitum.
Tumor
Lewis lung carcinoma (3LL) was initially supplied by the Aichi Cancer Center Institute. It was maintained by serial biweekly s.c. pas sage in C57BL/6crSlc mice. The tumor frag ments were stirred in RPMI medium 1640 (Gibco Laboratories, Grand Island Biological Co., Grand Island, NY), containing 0.05% trypsin, at 30°C for 30 min. After rinsing, the viability of the tumor cells was confirmed by the trypan blue dye exclusion method. A sus pension of 105 viable cells in 0.05 ml of RPMI 1640 was implanted s.c. into the footpad of each mouse.
Drugs
Cepharanthin was kindly provided by Kaken Shoyaku Co., Ltd., Tokyo. The anticancer agent, 5-FU (Kyowa Hakko Kogyo Co., Ltd., Tokyo) was used as a reference drug in some of the experiments. The required concentra tions of drugs were dissolved in 0.9% NaCI solution for the study.
Assay of lung metastases
When the implanted tumor in the footpad had become about 4 to 5 mm in diameter 10 days after implantation of tumor cells, the mice were anesthetized by i.p. injection of 1 mg of sodium pentobarbital, and the tumor bearing leg was then surgically amputated. Mice were killed 14 days after removal of the implanted tumor, and their organs were ex amined grossly. The gross numbers of metastatic nodules were counted by Wexler's method (18) .
Preparation of effector cells
Peritoneal exudate cells (PEC) were col lected by washing the peritoneal cavity with 10 ml of RPMI 1640, 4 days after i.p. injection of cepharanthin. PEC were washed 3 times with medium and suspended at a fixed concentra tion in RPMI 1640 containing 10% fetal calf serum (FCS). For separation of adherent cells, suspensions of PEC were put into plastic flasks coated with serum and incubated at 37°C in a 5% CO2 incubator to allow mac rophages to become attached by the method of Kumagai et al. (19) . After incubation for 20 min, nonadherent cells were decanted, and flasks were washed 5 times with medium in an ice bath. Adherent cells were then removed from the flasks by incubation at 4°C in medium containing 0.2% EDTA and 5% FCS, washed, and resuspended in RPMI 1640.
Assay of hepatic drug-metabolizing enzyme
The activity of hepatic drug-metabolizing enzymes was assayed by the production of col ored metabolites from aminopyrine and ani line after incubation with microsomes at 37°C in the presence of a NADPH-generating sys tem (20) as described below. For the prepara tion of microsomes, a 25% liver homogenate in 0.25 M sucrose was centrifuged at 10,000 X g for 20 min at 4°C. The supernatant fraction was aspirated and centrifuged at 105,000 X g for 60 min at 4°C. The microsomal pellet was washed by resuspension in ice-cold 0.15 M KCl-10 mM EDTA, followed by resedimenta tion at 105,000 X g for 30 min. The final pel let was resuspended in an isotonic KCl solu tion.
For the aniline hydroxylase assay, each in cubation mixture consisted of 5 uM aniline, 2 ,uM NADP+, 25 pM glucose-6-phosphate, 3.5 units of glucose-6-phosphate dehydrogenase, 25 ,u M magnesium chloride and 1.0 ml of mic rosomal suspension in a total volume of 5.0 ml buffered at pH 7.4 with 0.1 M potassium phos phate. Reaction was initiated by the addition of microsomes. Incubations conducted in tri plicate were carried out for 20 min at 37°C and terminated by the addition of 2 ml of 20% trichloroacetic acid. Precipitated protein was removed by centrifugation, and aliquots of the clear supernatant were assayed for p-ami nophenol at 630 nm in a spectrophotometer (Beckman Model 34, U.S.A.) according to the method of Kato and Gillette (21) .
Aminopyrine demethylase assay was per formed by the method of Farquhar et al. (20) . Formaldehyde production from aminopyrine was reacted with Nash's reagent and deter mined by the method of La Du et al. (22) at 412 nm in a spectrophotometer (Hitachi 181 UV-VIS, Japan).
Assay of 5-FU
The assay of 5-FU in the tissue was mea sured as 5-FU by a bioassay method using an indicator bacterium, Micrococcus luteus ATCC 10240 (23) .
Statistics
The values are expressed as the means ± S.E., and the statistical significances were de termined with Student's t-test. Probabilities of less than 5% (P < 0.05) were considered signi ficant.
RESULTS
Inhibition of growth of lung metastases by cepharanthin
The effect of cepharanthin on the growth of lung metastases of 3LL was examined by in jecting cepharanthin into mice after removal of the implanted primary tumor. As shown in Additive effects of cepharanthin and 5-FU on lung metastases
The effect of combined therapy with cephar anthin and 5-FU on lung metastases was ex amined. The development of lung metastases was inhibited by each of these treatments alone, and the effects were additive (Table 2) . In a preliminary experiment, the antitumor activity of the reference compound 5-FU at 30 mg/kg/day was most effective in suppressing tumor growth and prevention of lung metas tases. With a higher dose of 50 mg/kg, howev er, the anti-metastatic effect was weaker than that of the control saline-treated group be cause of 5-FU toxicity (data not shown). An optimal dose of 5.0 mg/kg of cepharanthin and 30 mg/kg of 5-FU were injected i.p., 3 times on days 10, 12 and 14 after tumor im plantation; this caused the most significant in hibition of lung metastases, and no metastatic nodules could be seen in 5 out of 10 mice. 
Inhibition of i.v. injection of peritoneal mac rophages activated with cepharanthin on lung metastases
Peritoneal adherent cells from mice acti vated with cepharanthin were injected i.v. on days 10, 12 and 14 into mice with lung meta stases after tumor implantation. As shown in Table 3 , a significant reduction in the number of metastatic nodules was observed in the lungs of mice given injections of peritoneal adherent cells activated with cepharanthin, but not in mice given injections of nonadherent cells treated with cepharanthin. Furthermore, no inhibition of metastases was seen in mice given injections of peritoneal adherent cells taken from normal mice. These results indi cate that the transfer of peritoneal mac rophages activated with cepharanthin has an inhibitory effect on lung metastases.
Effects of cepharanthin on drug-metabolism in the liver of 3LL-bearing mice A single dose of cepharanthin (5.0 mg/kg) or 5-FU (30 mg/kg) plus cepharanthin (5.0 mg/kg) was injected i.p. into mice on the day the implanted primary tumor was removed. As shown in Fig. 1 , aniline hydroxylase and aminopyrine demethylase activities of mice treated with cepharanthin (a single injection of 5 mg/kg) were significantly inhibited com pared to the saline-treated controls. The con trol values were as follows: aniline hydroxyl ase, 1.41 ± 0.092 (,uM/hr/g liver); aminopy rine demethylase, 2.98 ± 0.169 (,u M/hr/g liv er). Aniline hydroxylase activity was reduced more than aminopyrine demethylase activity. One day after the treatment with cepharanthin plus 5-FU, the activities for aniline hydroxyl ase and aminopyrine demethylase were re duced to approximately 48-60% of the con trols, and they slowly recovered with the elapse of time, but aniline hydroxylase activity in the liver of the mice treated with cepharan thin plus 5-FU remained inhibited even on the 5th day.
To examine whether cepharanthin has a modulating effect on the tissue 5-FU concen tration, mice were administered i.p. with cepharanthin (5 mg/kg) or cepharanthin plus 5-FU (30 mg/kg). The concentration of 5-FU in biological samples were measured as 5-FU at 6 hr after the last treatment with the drug. 5-FU was present to a much greater extent in the liver, kidney, spleen, lung, and blood when it was administered in combination with cepharanthin (Table 4) .
DISCUSSION
Tumor metastasis is established by a charac teristic series of steps involving interaction with the extracellular matrix and basement membranes (24, 25) . The inhibition and pre vention of metastases are important problems in cancer therapy. It may be possible to inhibit metastasis, which is usually fatal in patients with malignant neoplasms. However, it is diffi cult to prevent overt metastasis or primary tumor growth. We used 3LL as an ex perimental model of spontaneous lung mic rometastasis. In our model, the influence of the primary tumor on metastasis was excluded by removing the implanted tumor. Thus, this system seemed suitable for investigating the effects of host modulation on micrometastasis. We previously described that a blended Chinese medicine, Shosaiko-TO, inhibited the development of lung metastases in this model (8) . Ono (26) has observed that oral adminis tration of cepharanthin to tumor-bearing mice resulted in inhibition of 3LL primary tumor growth, preferential suppression of pulmonary metastases, and prolongation of survival time. By itself, cepharanthin was effective in pre venting lung micrometastasis in syngeneic mice after the removal of 3LL implanted in the footpad (Table 1) . We found that cepharanthin plus 5-FU had additive inhibitory effects in an experimental lung metastasis model (Table 2) . Several inter pretations of this are possible: 1) The liver drug-metabolizing system was suppressed by treatment with cepharanthin ( Fig. 1) , resulting in the increase of 5-FU in the tissues.
2) The cytotoxicity of 5-FU was enhanced by the administration of cepharanthin.
3) The tumor cells sterilized by 5-FU might have released abundant antigens, which led to an enhanced immune response. Although the present re sults do not clarify what mechanism is in volved in the combined effect, the ex perimental results indicate that cepharanthin can serve as an excellent adj uvant to antican cer drugs.
Shimura has been reported that cepharan thin enhanced phagocytosis in the peritoneal macrophages of mice and the third component of the complement system was activated by the i.p. injection of cepharanthin (17) . Ito et al. (27) reported that adherent PEC, har vested from mice after i.p. injections of squalene-treated Nocardia rubra cell wall skeleton, showed cytolytic activity on tumor target cells in vitro. They also found that this activity was markedly inhibited by treatment with antimacrophage serum and complement or carrageenan. Moreover, Liotta et al. (28) reported that the i.v. transfer of BCG-acti vated peritoneal exudate cells inhibited lung metastasis in mice that had been implanted with T241 fibrosarcomas. Furthermore, Sone et al. (29) demonstrated that after direct stimula tion with Nocardia rubra cell wall skeleton, alveolar macrophages became tumorcidal against syngeneic, allogeneic and xenogeneic tumor cells in vitro. We have here demon strated that i.p. injections of adherent PEC activated with cepharantin inhibit the develop ment of lung micrometastasis in mice. In addi tion, the antimetastatic effect was not observed when 3LL-bearing mice were in jected i.p. with a blocker of immunocompe tent cells, carrageenan (2 mg/mouse) on days 10, 12 and 14 after tumor implantation (H. Ito et al., unpublished data 
